News of Note—GlaxoSmithKline, Ebola and SK Bioscience

newspaper
In this week's news of note, the World Health Organization declared an end to the Ebola outbreak in Congo. (Pixabay)

Here is some other vaccine news of note for the week.

> GlaxoSmithKline has reported £1.25 billion ($1.65 billion) in second-quarter vaccine sales, a 16% increase at constant currencies. Reuters story

> The World Health Organization has declared an end to the Ebola outbreak in the Democratic Republic of Congo. Release

> South Korea's SK Bioscience is spending $89 million on a plant to increase vaccine capacity. Pulse story

Read more on
Ebola GlaxoSmithKline Shingrix

Suggested Articles

shingrix
Vaccines

GSK's Shingrix supply will leap up, CEO says—in 2024, that is

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

by Eric Sagonowsky
Merck
Vaccines

Merck makes history with world's first Ebola shot approval

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

by Eric Sagonowsky
Vaccines

Cosette to add liquids to its mix with deal for 2nd plant

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

by Eric Palmer